US patent lawsuit filed against Genmab and Janssen regarding Darzalex

5 April 2016

Danish biotech firm Genmab (OMX: GEN) announced yesterday that Germany’s MorphoSys (MOR: DE) apparently has filed a complaint at the US District Court of Delaware against Genmab and its collaboration partner Janssen Biotech, for patent infringement under US patent no. 8,263,746 based on activities relating to manufacture, use and sale of Darzalex (daratumumab) in the USA.

The US patent relates to CD38 antibodies defined by functional features. MorphoSys confirmed it is taking such action

Darzalex is approved in the US for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent and a marketing application has been submitted in the European Union for daratumumab for use in patients with relapsed and refractory multiple myeloma by Janssen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK